Novavax's updated Covid vaccine can still catch up to Pfizer, Moderna shots this fall
Publishing timestamp: 2023-10-07 08:00:02
Summary
Novavax's updated Covid vaccine has been approved by U.S. regulators, and analysts believe the company is well positioned to compete in the U.S. Covid vaccine market. The vaccine's arrival comes after logistical issues hampered the rollout of other shots. Novavax's vaccine is seen as a valuable alternative to mRNA shots from Pfizer and Moderna, and the company is working to strengthen its financial position. The authorization label for Novavax's new vaccine is broad, allowing for wide accessibility. The company's stock jumped after FDA clearance. Novavax's vaccine is entering the market at a time when demand for Covid vaccines is expected to peak in the fall and winter. The biggest uncertainty for all vaccine companies is how many Americans will decide to get another Covid vaccine.
Sentiment: POSITIVE
Tickers: NVAX, WBA, MRNA, PFE,
Keywords: science, coronavirus, walgreens boots alliance inc, breaking news, covid-19 vaccine rollout, pfizer inc, novavax inc, health care industry, biotech and pharmaceuticals, covid-19, business, immunizations, biotechnology, pharmaceuticals, united states, moderna inc, business news,